AU
UK
CA
NZ
IND
US
The latest analysis, expanding the company’s 2023 data, examined a cohort of 20,000 patients and reaffirmed previous findings on the effectiveness of the Shield blood-based colorectal cancer screening test. Shield, the first FDA-approved blood test for primary CRC screening among average-risk adults aged 45 …
Nanobiotix(NASDAQ:NBTX)reported updates on the JNJ-1900 clinical program following the transfer of NANORAY-312 Phase 3 trial sponsorship and operational control to Johnson & Johnson. The transfer, which began in 3Q2024, covers most regions and includes full operational oversight of the trial.
X4 Pharmaceuticals(NASDAQ:XFOR)announced the pricing of its underwritten public offering of 45,860,000 shares of common stock at USD 2.90 per share. The company also issued pre-funded warrants allowing certain investors to purchase up to 700,000 shares at USD 2.899 per warrant. These warrants have an …
Sanofi(NASDAQ:SNY)and Medidata, a brand under Dassault Systèmes, announced the renewal and expansion of their decade-long partnership to advance clinical research. Under the extended agreement, Sanofi will deploy Medidata Patient, Data, and Study Experiences to connect previously separate clinical trial tools, streamline operational workflows, minimize …
Shuttle Pharmaceuticals Holdings(NASDAQ:SHPH)continues to advance its lead candidate, Ropidoxuridine (IPdR), a drug designed to selectively sensitize cancer cells to radiation while protecting healthy tissue. The compound is currently under investigation in glioblastoma, one of the most aggressive brain cancers.
Pfizer Inc. (NYSE:PFE) has released updated follow-up results from the Phase 2 PHAROS trial, evaluating the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for adults with metastatic non-small cell lung cancer (mNSCLC) carrying the BRAF V600E mutation. In treatment-naïve participants, median overall survival (OS) …
Equities research analysts have recently adjusted their ratings for Lucid Diagnostics (NASDAQ:LUCD). Wall Street Zen upgraded the stock from a "sell" rating to a "hold" rating in a report released Tuesday. Needham & Company LLC maintained a "buy" rating and set a USD 3.00 …
NovoCure Limited (NASDAQ:NVCR) has received an average recommendation of“Hold”from eight analysts covering the company, as reported by MarketBeat Ratings. Of these analysts, one assigned a“Sell”rating, three rated it as“Hold,”and four gave a“Buy”rating. The collective 12-month price target across these brokerages averages USD 27.50.
William Blair reiterated its outperform rating on Autolus Therapeutics (NASDAQ:AUTL), reinforcing a broadly positive analyst sentiment for the clinical-stage biotech firm. Needham & Company echoed this view with a “buy” rating and a USD 10.00 price target, while Wells Fargo trimmed its target to …
Organogenesis Holdings Inc. (Nasdaq:ORGO) announced an update on its second Phase 3 randomized controlled trial (RCT) of ReNu®, a cryopreserved amniotic suspension allograft (ASA) for symptomatic knee osteoarthritis (OA). While the study did not achieve statistical significance for its primary endpoint, the results showed …
Please wait processing your request...